Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.
Ravi Madan, MD
Advertisement
Articles by Ravi Madan, MD
Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide
Advertisement
Latest Updated Articles
Ravi A. Madan, MD, Discusses the Significance of the PEACE-1 Trial With Docetaxel, Abiraterone, ADT, and Radiotherapy in mCSPCPublished: October 6th 2021 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
SCT with Melphalan/Ascorbic Acid Safe for BRCA-Mutated PDAC
3
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
4
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
5
